Mieloma m?ltiple - Gu?a para el paciente
Edici?n 2008/2009
IMF DNA BANK IDENTIFIES GENETIC VARIATIONS RELATED TO PREDISPOSITION TO MM AND RESPONSE TO TX
LIGHTS, CAMERA, CURE! The IMF's 15th Anniversary Gala a Winner!
1070
Blood Drive dedicated to IMFer Michael Tuohy
The Role Of The Ras Oncogene In Multiple Myeloma Spread
Autologous Bone Marrow And Stem Cell Transplantation For Multiple Myeloma, part 1
Myeloma Minute - January 18, 2006
Autologous Bone Marrow and Stem Cell Transplantation For Multiple Myeloma, part 2
SZPICZAK MNOGI PORADNIK DLA PACJENT?W
Myeloma Minute - October 25, 2007
Guida Per Il Paziente
Introduction to Proteasome Inhibition
THE FIVE PRINCIPLES
THE INTERNATIONAL MYELOMA FOUNDATION CONGRATULATES FRIEND AND COLLABORATOR DR. LUC MONTAGNIER FOR BEING AWARDED THE NOBEL PRIZE
IMF Multiple Myeloma Patient Handbook 2008/2009

VELCADE^® (Bortezomib) verstehen
Conociendo VELCADE® (bortezomib) para inyección
IMF Sponsors Symposium Preceding 46th Annual ASH Meeting
Hastalara y?nelik ek kitabı
BANK ON A CURE® "GENE BANK" RESEARCHERS IDENTIFY PATHWAYS THAT MEDIATE SIDE EFFECTS FROM WIDELY-USED MYELOMA TREATMENT
INTERNATIONALE MYELOMSTIFTUNG: MEHRERE STUDIEN AUF GLOBALER KREBSKONFERENZ ZEIGEN DIE VERBESSERUNG DER AUSSICHTEN FÜR BLUTKREBSPATIENTEN DURCH NEUE THERAPIEN
ASH 2005 G?ncel ?zet
THE INTERNATIONAL MYELOMA FOUNDATION: MULTIPLE STUDIES AT GLOBAL CANCER CONFERENCE SHOW NEW THERAPIES CHANGING THE OUTLOOK FOR PATIENTS WITH BLOOD CANCERS

LA FONDATION INTERNATIONALE DU MYÉLOME: DES ÉTUDES MULTIPLES PRÉSENTÉES À LA CONFÉRENCE MONDIALE DE CANCÉROLOGIE INDIQUENT QUE LES NOUVELLES THÉRAPIES CHANGENT LE PRONOSTIC DES PATIENTS ATTEINTS DE CANCER DU SANG

LA FUNDACIÓN INTERNACIONAL DEL MIELOMA: MÚLTIPLES ESTUDIOS EN LA CONFERENCIA MUNDIAL DEL CÁNCER DEMUESTRAN QUE LAS NUEVAS TERAPIAS ESTÁN CAMBIANDO EL PRONÓSTICO DE PACIENTES CON CÁNCER DE SANGRE

February 13, 2004 Myeloma Minute
Excerpts from Acceptance Speeches at Cirque de la Vie
What's New In Research - February 12, 2004
Applying For An International Myeloma Foundation Research Grant
EMEA Marketing Approval of REVLIMID® is Important Advance for Patients in Europe
14th Anniversary Ribbon of Hope Gala Honorees:
QUALITY OF LIFE AWARD
IMF 2001 Research Grant Awards
IMF 2000 Research Grant Awards
The Role Of Osteoclast Differentiation Factor TRANCE in Myeloma-Associated Bone Destruction
IMF 1999 Research Grant Awards
Immune-Mediated Clearance Of AL-Amyloid
Dendiric Cell-Based Vaccination With Idiotype For Amyloidosis And Post-Transplant Myeloma
Isolation Of Myeloma-Cytotoxic T Lymphocytes - Identification of Myeloma Tumor Antigents
Targeted Radioimmunotherapy For The Treatment Of Myeloma: A Preliminary Pharmacodynamic Study
1998 IMF Research Grant Awards
Kaposi's Sarcoma-Associated Herpesvirus Cytokines in the Oncogenesis of Multiple Myeloma
Characterization of 14q32 Translocations In Multiple Myeloma
Moncolonal Antibody Directed Immunotherapy For The Treatment Of Multiple Myeloma
Molecular Mechanisms Of Myeloma Cell Resistance To Apoptosis
1997 IMF Research Grant Awards
IMF 1996 Research Grant Award
IMF 1995 Research Grant Award
IMF to Establish European Base of Operations in Germany
Myeloma Minute - December 7, 2005
FDA Approves Aredia For The Treatment Of Myeloma Bone Disease
Important New Blood Cancer Initiative Announced on Capital Hill
What's New In Research - May 23, 2003
The Unknown Patient Reports from the IXth International Myeloma Workshop
IXth International Myeloma Workshop - Thursday, May 22nd, 2003
Complementary and Alternative Medicine
Richie Test
Barisa's Test
The Page You Requested Is Not Available
多発性骨髄腫
患者の手引き
СПРАВОЧНИК ПАЦИЕНТА
Множественная Миелома
Рак Костного Мозга
2007

Patientenhandbuch
Robert A. Kyle, MD
Forming A Myeloma Support Group
June Brazil in Memoriam
Upcoming Professional Meetings
Forming A Support Group - Sample Flyer
Sample Support Group Newsletter
June, 2001 Senate Hearing on Blood Cancer Research: A personal photo journal
Senate hearing on Blood Cancer Research
LE MY?LOME MULTIPLE - GUIDE DU PATIENT

Report from the Kyoto Seminar 2005
The IMF?s Debbie Birns Visits AMEN
Tom Bay, Noted Author and Motivational Speaker, joins IMF Board of Directors
Conociendo la Cifoplastia con Bal?n y las Fracturas Vertebralescon Aplastamiento producidas por el Mieloma
October 15, 2003 Myeloma Minute
Rockin' the Night Away!
The Ribbon of Hope Gala in Seattle 2003
October 24, 2003 Myeloma Minute
Fiesta for a Cure! - Silent Auction Items
Fiesta for a Cure! - Prizes
Breve Relazione della malattia e delle opzioni terapeutiche
Mieloma Multiplo Tumore del midollo osseo
Conoscere e capire il dosaggio delle Catene Leggere Libere nel Siero

High-Dose Melphalan in the Era of New Effective Agents
The Potential Role of Novel Combinations in Frontline Therapy
The Importance of Achieving Complete Remission (CR
Does the Percentage of Complete Response with New Drugs Determine Ultimate Survival?
The Safety Issue Surrounding Maintenance Therapy
Myeloma Minute - June 20, 2004
Have an Old Cell Phone?
Turn It Into Dollars for a Cure
Does Maintenance Therapy Improve Time to Progression and Ultimate Survival?
Is Double Transplant Better Than Single Transplant?
Tandem vs Single Transplant: Which is Better for Whom?
Role of New Drug Trials at Relapse
IMF Research Grant Summary (1995-2004)
Myeloma Quilt of Courage #4 - Frankie Salgado
Myeloma Quilt of Courage #4 - Frankie Salgado
What's New In Research - November 1, 2003
November 1, 2003 Myeloma Minute
Medicare Proposals Threaten Access to Care
Appropriations Update
November 9, 2003 Myeloma Minute
Concise Review 2003 - Japanese Edition
Revue de la Maladie et des Options Therapeutiques
Dear Reader
News and Notes
Ask the Expert:
The Pathogenesis and Treatment of Multiple Myeloma Bone Disease
IMF Support Group Leader Retreat
The Good, the Bad, and the Ugly of Cancer Public Policy
IMFer Profile: Terry Herman Shares Her Story
Scientific Advisor Profile: Meet New Members of the IMF Scientific Advisory Board
Rafael Fonseca, M.D.
John Gibson, M.D., Ph.D.
Kazuyuki Shimizu, M.D.
Jan Westin, M.D., Ph.D.
She's Banking on Finding a Cure
Congressional Conferees Move Closer to Medicare Agreement
Write to Congress
Phase II REVLIMID? Trials
November 16, 2003 Myeloma Minute
The IMF Visits Italy and France
Myeloma Patients and Oncology Nurses to Benefit from IMF/Millennium Collaboration
Veterans, Agent Orange, Multiple Myeloma, and VA Benefits
It?s Your Attitude... It?s Your Choice
Early studies indicate targeted radioactive drug may expand treatment options for myeloma
Letters
News and Notes
Medicare and Appropriations Bills Threaten to Leave Most Cancer Patients Behind
What's New In Research - November 24, 2003
The Gift of Giving
November 26, 2003 Myeloma Minute
Eric Vogt
Valerie Holloway
Charles "Chuck" Thompson
Steven Howell
Jacklyn Inman
Robert Heeren
Lorna Newlin
Pennie Lawrence
Marvin Mason
Ralph D'Errico
2004 Research Grants Awarded to the Best
IMF Announces Key Worldwide Funding
OVAC Urges the Senate to Support Funding Increases to Cancer Research and Program Funding!
Opening of National Oncologic PET Registery Hits Snag.
Confusing news stories about the efficacy of thalidomide. What does this all mean?
Past Recipients of the Robert A. Kyle Lifetime Achievement Award
Robert A. Kyle Lifetime Achievement Award
IMF PRESENTS THE KYLE LIFETIME ACHIEVEMENT AWARD TO MARIO BOCCADORO, MD, OF THE UNIVERSITY OF TORINO, ITALY
Sponsorship Opportunities for the Fourth Annual Robert A. Kyle Lifetime Achievement Award
Reporte desde Madrid
Understanding Bisphosphonate Therapy
Why Should I Attend an IMF Patient & Family Seminar? Testimonials
NIH Announces Program to Foster the Independence of New Investigators
Multiple Strategies for Treating Myeloma: Case Discussions
Elise Segar and Red Dot Match Funds for the IMF
Myeloma Minute - February 1, 2006
Thank You IMFers
In Search Of The Myeloma Stem Cell: A Special Report
ASH 2003: An Avalanche of New Information
What does it all mean, and where do we go from here?
What's New In Research - December 22, 2003
December 23, 2003 Myeloma Minute
Phase I VELCADE® Clinical Trials
You are now leaving the IMF website and are accessing the Ortho Biotech homepage.
WAITING
Understanding VELCADE® (bortezomib) for Injection Therapy
New opportunity for American Express Cardholders to support IMF
VELCADE® (bortezomib) for Injection
testing google free search
January 20, 2004 Myeloma Minute
Advocacy Update: Federal Support for Cancer Issues in Decline
Did You Know?
Immunizations in myeloma patients
Medicare Changes Impact Care
Senate Passes Funding Bill; Includes Money for Myeloma Community
2nd Annual Cancer Survivorship Telephone Education Workshop Series, Cancer Survivorship
January 29, 2004 Myeloma Minute
PRESS OFFICE
MEDIA ALERT - MINNEAPOLIS PATIENT & FAMILY SEMINAR
February 26, 2004 Myeloma Minute
Message from IMF President
Advocacy Update: Congress Adjourns
News and Notes
Report from the Sixth Annual Support Group Leaders' Retreat
July 8-10, 2005
Ask the Expert: What's New with the Use of VELCADE^TM in MM?
Who is the Unknown Patient?
Did You Know?
Important New Blood Cancer Initiative Announced on Capitol Hill
CTSU Independent Clinical Research Site (CICRS) Initiative
IMF Christmas Cards With Original Jr. IMFer Art
Drug Compendia List Revlimid for Frontline Treatment of Myeloma
Report from the Inaugural IMF - China Myeloma Symposium
October 20, 2007 in Beijing, China.
Myeloma Minute - November 6, 2007
Myeloma Minute - June 9, 2005
Die Bisphosphonat-Therapie verstehen
Una explicaci?n de la Terapia con Bisfosfonatos
Comprendre la Therapie aux Bisphosphonates
Connaître VELCADE® (bortézomib) pour Injection 2006
Program Highlights from the 10th International Workshop in Myeloma
The Myeloma Matrix Part III (Pre-Clinical)
Celebrating a Life
Torino Myeloma Conference
April 22, 2004
Torino Myeloma Conference
April 23, 2004
Torino Myeloma Conference
April 24, 2004
IMF Receives Million Dollar Grant from Centers for Disease Control and Prevention
Myeloma Minute: Important News from Washington
Celebrating a Life: IMFer Gerry Difford
Myeloma Minute: Special Advisory On Osteonecrosis Of The Jaws
The IMF Advocates Formal Approval of Thalomid(R) for Myeloma
Myeloma Minute - May 21, 2004
Update From ASCO 2004: Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN
Update From ASCO 2004: Ivan Borrello, MD, Johns Hopkins University, Baltimore, MD
Paul Richardson, MD, Dana Farber Cancer Institute, Boston, MA
William Matsui, MD, The Myeloma Stem Cell
International Myeloma Foundation Heralds ECOG Announcement
BLTD Protocol
Morton Coleman, MD, Weill Medical College, Cornell University, New York, NY
Brian G.M. Durie, MD, Cedars Sinai Medical Center, Los Angeles, CA
Sundar Jagannath, MD, St. Vincents Comprehensive Cancer Center, New York, NY
Sundar Jagannath, MD, St. Vincents Comprehensive Cancer Center, New York, NY
Robert A. Kyle, Mayo Clinic, Rochester, MN
Jamie Cavanagh, St. Bartholomew's Hospital, London, UK
William Bensinger, MD, Fred Hutchison Cancer Research Center, Seattle, WA
William Bensinger, MD, Fred Hutchison Cancer Research Center, Seattle, WA
Gareth Morgan, MD, Leeds General Infirmiry, Leeds, UK
Mohamad A. Hussein, MD
Leader, Multiple Myeloma Clinical Research
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida
testing verisign seal
Report from Tokyo 2004 Patient and Family Seminar
MYELOMA MINUTE SPECIAL EDITION - REPORT FROM ASCO 2004
testing
IMF
Antonio Palumbo, MD, of The Italian Multiple Myeloma Study Group
test
A. Palumbo, MD, The Italian Multilple Myeloma Study Group
Antonio Palumbo, MD, of The Italian Multiple Myeloma Study Group
Robert M. Rifkin, MD, Rocky Mountain Cancer Centers, US Oncology, Denver, CO
Fighting Myeloma at Sea!
IMF's Centers for Disease Control and Prevention (CDC) grant renewed for second year
Advocacy Update: Support for Cancer Priorities Short-Changed in President?s Budget
Understanding Stem Cell Transplant
MULTİPL MİYELOM
Phase III VELCADE® Clinical Trials
Phase I/II VELCADE® Clinical Trials
Consensus Panel Session Introduction
Slide Set from the 2009 ONS Annual Congress Satellite Symposium
Leading the Way: Managing Multiple Myeloma for the Long-Term

Simultaneous vs. Sequential Use of Novel Agents in Induction Therapy
Fighting Myeloma at Sea! - Jerry Eisenhower's Maritime Journal
MYELOMA MINUTE SPECIAL UPDATE:
THALIDOMIDE TO BE COVERED IN MEDICARE DEMONSTRATION PROJECT
Online Support Group -- a.k.a., the ListServ
BERMUDA :?THE 3RD IMF SCIENTIFIC ADVISORS RETREAT
Focus on Molecular Testing and Clinical Trials
Report from ASCO 2004: MYELOMA FRONTLINE THERAPY IN THE SPOTLIGHT
Aredia/Zometa and osteonecrosis of the jaws
A New Update - July 2004
Myeloma Manager™ News
THE INTERNATIONAL MYELOMA FOUNDATION SAYS REVLIMID? MEETS IMPORTANT QUALITY OF LIFE MEASURES
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW TREATMENT REGIMEN FOR OLDER PATIENTS COULD SOON BE APPROVED IN EUROPE
Major Medical Conference Points to Improved Treatment and Survival Options for Blood Cancers

KOS 2007: International Staging System for Multiple Myeloma

KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
International Myeloma Foundation Supports Senator Hutchison Initiative
Greetings from Australia
Pictures from the Philadelphia Patient and Family Seminar - October 17-18, 2003
Myeloma Minute - July 27, 2004
14th Anniversary Ribbon of Hope Gala Honorees
14th Anniversary Ribbon of Hope Gala Sponsors
14th Anniversary Ribbon of Hope Gala Honorees:
COURAGE AWARD
14th Anniversary Ribbon of Hope Gala Honorees:
GUEST OF HONOR
14th Anniversary Ribbon of Hope Gala Honorees:
VISIONARY AWARD
Pictures from the San Jose Patient and Family Seminar
July 16-17, 2004
Medicare eligible? Apply NOW to save 90% of thalidomide costs!
Myeloma Minute - August 2, 2004
Myeloma Minute - July 27, 2004
Third Annual Myeloma Awareness Week (August 20 -30)
IMF Raises Awareness of little known Cancer
Michio M. Kawano, MD
QUARTERLY UPDATE FROM BANK ON A CURE?
February 2004
IMPORTANT INFORMATION ABOUT THE MEDICARE DEMONSTRATION PROGRAM
QUARTERLY UPDATE FROM BANK ON A CURE?
Summer 2004
First Myeloma-Specific Cancer Patient DNA Bank Becomes a Reality
Special Myeloma Minute: Medicare eligible? Apply NOW to save 90% of thalidomide costs!
Myeloma Minute - August 18, 2004
I'm Not Leavin'
by Michael Tuohy
IMF Welcomes Multiple Myeloma Research Consortium to Team
The IMF at Work in Washington
IMF Urges Medicare to Add Thalidomide to Demonstration Project
IMF Receives Million Dollar Grant from Centers for Disease Control and Prevention
14th Anniversary Ribbon of Hope Gala Auction
14th Anniversary Ribbon of Hope Gala Auction - Travel
14th Anniversary Ribbon of Hope Gala Auction - Entertainment
Applications to Medicare Demonstration Project Far Below Expectations
CMS May Limit Off-Label Coverage For Cancer Drugs To Clinical Trials
The IMF Presents the 2nd Annual Myeloma Awareness Week
Myeloma Minute - September 30, 2004
International Myeloma Foundation Privacy Statement
Guide to Drug Names
IMF WALL OF MIRACLES
A Comprehensive Guide to Torino Multiple Myeloma 2004 Conference
Myeloma Minute - October 17, 2004
Jayesh Mehta, MD
What would be the significance of FDA Approval of Thalidomide for Myeloma?
Myeloma Minute - October 26, 2004
The Benefits of Adding Thalidomide to a DVd Regimen
REPORT FROM THE 14th ANNIVERSARY RIBBON OF HOPE GALA
San Diego Patient & Family Seminar a Sold Out Success
14th Anniversary Ribbon of Hope Gala Honorees:
RIBBON OF HOPE AWARD
IMF "Ask the Expert" Video: Donna Weber, MD
M.D. Anderson, Houston, TX
CITINGS
ASH 2004 Webcast
Myeloma Minute - December 3, 2004
YOUR IMF DOLLARS AT WORK
CURRENT U.S. EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT
OVERVIEW OF KYPHOPLASTY IN THE MANAGEMENT OF SPINAL TUMORS
APEX
PAD COMBINATION THERAPY FOR PREVIOUSLY UNTREATED PATIENTS
EVALUATION OF THE PATIENT IN INITIAL RELAPSE AND SELECTION OF SECOND-LINE THERAPEUTIC OPTIONS
OSTEONECROSIS OF THE JAWS IN MYELOMA:
Time Dependent Correlation with AREDIA and ZOMETA Use
NEW APPROACHES TO MYELOMA STAGING AND FRONT-LINE TREATMENT SELECTION
New, Improved Staging System for Multiple Myeloma Developed for Use Around the World
PRELIMINARY CASE EVALUATION: AN INTERACTIVE ASSESSMENT OF AUDIENCE TREATMENT OPTIONS
SUPPORTIVE CARE AND THE MANAGEMENT OF THE NEWLY DIAGNOSED AND INITIALLY RELAPSING PATIENT
CURRENT EUROPEAN EXPERIENCE WITH TRANSPLANTATION AND MANAGEMENT OF THE NEWLY DIAGNOSED PATIENT
CONTROVERSIES IN MYELOMA MANAGEMENT
Diagnosis, Initial Treatment and the Relapsing Patient
Primary Treatment with Pulsed MDT in Symptomatic Elderly Patients
Pilot Study Evaluating the Safety & Efficacy of AMD3100 ...
Randomized Trial Comparing MP, MP-THAL and MEL100 for Newly Diagnosed Pts Aged 65-75 Years
ECOG Clinical Trials in Myeloma For Newly-Diagnosed Patients
Fonseca
Antibody-Based Therapy Targeting Myeloma Stem Cells
A Phase I, Multi-Dose Study of SGN-40 (anti-huCD40 mAb) in Patients with MM
Bortezomib as First-Line Therapy in Patients with MM; A Multicenter Phase 2 Clinical Trial
DEVELOPMENT, PREDICTION, AND TREATMENT OF ANEMIA IN PATIENTS WITH LYMPHOMA/MM
Depsipeptide in the Treatment of Relapsed and Refractory MM: A Prospective Evaluation
MPT vs MP: INTERIM ANALYSIS PROSPECTIVE RANDOMIZED TRIAL NEWLY DIAGNOSED PATIENTS AGE > 65 YEARS
A Randomized Phase III Trial of Thal/Dex vs Dex in Newly Diagnosed MM (E1A00)
Phase 2 Trial of Single Agent Bortezomib in Patients with Previously Untreated Multiple Myeloma
Bortezomib Vs High-Dose Dexamethasone in Relapsed MM: Results of a Large Randomized Phase 3 Study
Phase I/II Nat'l Open-label Study of Bortezomib + Melphalan + Prednisone in Elderly Untreated MM Pts
Poorer Survival in Multiple Myeloma Correlates with Patients? Age...
THAL + DEX IS EFFECTIVE SALVAGE REGIMEN FOR PTS RELAPSING AFTER AUTOLOGOUS TRANSPLANT
Siegel
Sundar Jagannath, MD
VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.
Rodriguez ASH
[4869] IL-101082-A and TNF-Alpha 238/308A Genotypes Associated with Earlier (< 55) Onset of MM
REPORT FROM THE IMF- AND ICHE-SPONSORED
CONTROVERSIES IN MYELOMA MANAGEMENT
Clin. implications of t(11;14)(q13;q32), t(4;14)(p16;q32) and -17p13 (p53) deletions in pts with HDT
IMFer Michael Katz Receives Certificate of Appreciation from National Cancer Institute
CASE EVALUATION REVISITED
International Myeloma Foundation (IMF) to Bring Highlights from Prestigious International Myeloma Wo
Message from IMF President
Why Bank On A Cure??
Treating Multiple Myeloma: The Little Rock Approach
The Genetics of Multiple Myeloma
Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the Proteasome
Education Initiative
Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma
Cancer Research and Medicare: Political Pork?
IMF Kicks Off 2004 Seminars with Florida Retreat
Los Angeles Area Support Group Salutes Leader
IMFers Pay Tribute To Janet Johnson
International Myeloma Foundation Celebrates Landmark Success of 2004
One Voice Against Cancer
Letter to President Bush
One Voice Against Cancer Lobby Day
Spotlight on The Myeloma Foundation of Australia
Federal Cancer Policy: The Big Picture and its Consequences
The IMF Latin America
Myeloma Minute - February 10, 2005
Did You Know?
The Gift of Good Nutrition
Ask the Expert: Thalidomide and the ImiDs
Research Progress Report: Dr. Ivan Van Riet
YOUR GIFTS AT WORK: 2003 Brian D. Novis Research Grant Awards
News & Notes
My New First Birthday
IMF Receives Four-Star Rating from America's Largest Charity Evaluator
Man raises awareness of myeloma: Profile of Peter Tischler
Myeloma Minute - March 20, 2005
Dallas 2005 Patient & Family Seminar
Myeloma Minute - Coming to a City Near You!
Charity Navigator Gives IMF Highest Rating Available
IMFers Share Their Thoughts
Patient Perspective: Tracking My Numbers
Patient Perspective: My New First Birthday
Message from the IMF President
ASH 2004: The Avalanche of Information Continues
New Developments in Multiple Myeloma
The Expanding Role of Proteasome Inhibition in Multiple Myeloma
IMFer Profile: Andy Lebkuecher
Meet the New IMF Director of Support Groups
Wnt/ß-catenin Signaling in Multiple Myeloma
The Myeloma Matrix Part IV (Pre-Clinical con't)
North Texas MM Support Group
Myeloma Minute Special Edition: Important VELCADE® News
Katie's Birthday
The Touching Story of a Little Girl's Love
Sydney 2005:
Welcome
Sydney 2005:
Unconventional Switched Bone Marrow Plasma Cells with Ig V-region Mutations
Sydney 2005:
Cell Cycle Control of Multiple Myeloma Pathogenesis
Sydney 2005:
Cross-talks Between Plasma Cells and the Microenvironment: Triggering and Targeting
Sydney 2005:
Immunophenotype of the Malignant Clone ? Implications on Management
Sydney 2005:
Clinical and Biologic Implications of Genomics in Myeloma
Sydney 2005:Pathogenic Events Identified by Chromo. Translocations & Cyclin D Exp. Determine Myeloma
Sydney 2005:
Pathogenesis of Myeloma: Ig Translocations, Cyclin D Dysregulation, Other Events
Sydney 2005:
Epigenetic Changes in the Molecular Pathology of Multiple Myeloma
Sydney 2005:
Alternative Gene Splicing in Myeloma; Aberrant Splicing of Hyalur.
Sydney 2005:
Is Thalidomide First Line Therapy?
Sydney 2005:
Thalidomide and Cardiovascular Complications in MM
Sydney 2005: Opening Ceremonies
Sydney 2005:
New Advances in the Management of Myeloma Bone Disease
Sydney 2005:
Plasmapheresis in Renal Failure
Sydney 2005:
Prevalence, Pathogenesis & Treatment of Anemia with Erythropoetic Agents in MM
Sydney 2005:
Epidemiology of Multiple Myeloma
Sydney 2005:
Smoldering MM: Criteria for Diagnosis & Results of Long-Term Follow-Up
Sydney 2005:
The Evolving vs Non-Evolving Nature of Asymptomatic Monoclonal Gammopathies
Sydney 2005:
The International Staging System for Myeloma: An Update
Sydney 2005:
Advances in Diagnosis and Imaging in MM
Sydney 2005:
Normal Plasma Cell Development and Pathogenesis of MGUS and MM
Sydney 2005:
Cell. Model for MM Cell Growth & Differentiation Based on Intra-clonal CD45 Microenv
Sydney 2005:
Intercellulalar Communication Signals Determined by Gene Expression Profiling in MM
Sydney 2005:
The Funcation and Movement of CD45 Molecule in IL6-induced MM Cell Expression
Sydney 2005:
Maintenance Therapy After Autologous Stem Cell Transplantation: IFM99 Trial
Sydney 2005:
What Have the Transplant Registries Taught Us?
Sydney 2005:
HDT Options for Elderly Myeloma Patients: Results of a Randomized Controlled Trial
Sydney 2005:
Total Therapy for Newly Diagnosed MM: the Arkansas Experience
Sydney 2005:
Is Double Autograft the Standard of Care?
Sydney 2005:
Pathogenesis of Myeloma Bone Disease
Sydney 2005:
Osteoblast Function in Myeloma (endothelin 1, osteoblast proteosome)
Sydney 2005:
Bisphosphonates and the Bone Microenvironment
Sydney 2005:
Mouse Model in Tumour Microenvironment and Bone Disease
Sydney 2005:
Lenalidomide (CC-5013, Revlimid?) and Other IMiDs
Sydney 2005: Pegylated Doxorubicin in Combination w Immune-modulators & Arsenic
Sydney 2005:
Overview of New Therapies and Future Directions
Sydney 2005:
The Influence of the Tumour Microenvironment on Drug Response & Drug Resistence
Sydney 2005:
Angiogenesis in Myeloma - An Overview
Sydney 2005:
New Antiangiogenic Agents
Sydney 2005: Targeting of VEGF and PDGF Signaling by Receptor Tyrosine Kinase Inhibitors Impairs...
Sydney 2005: Molecular Mechanism Involved in Homing and Migration of Plasma Cells to the Bone Marrow
Sydney 2005:
Mechanisms of Oncogenesis in Waldenstrom's Macroglobulinemia
Sydney 2005:
Novel Insights into the Biology & Therapy of Waldenstrom's Macuglobulinemia
Sydney 2005:
Treatment of Waldenstrom's Macroglobulinemia
Sydney 2005:
Amyloidosis
Sydney 2005: Cryoglobulinaemia, POEMS and Gammopathy Associated Neuropathy
Professor Jean-Luc Harousseau Receives Prestigious Waldenstrom Award for a Lifetime of Achievement
Daily Update from International Myeloma Workshop - April 11, 2005
Myeloma Minute - February 28, 2006
Sydney 2005: In MM 14q32 Transloc. are Present in Memory B Cells but RAS Mutations are Restricted...
Daily Update from International Myeloma Workshop - April 12, 2005
Daily Update from International Myeloma Workshop - April 13, 2005
Daily Update from International Myeloma Workshop - April 14, 2005
Sydney 2005: The Transcriptome of MM Defines Disease Subgrps w/ Distinct Genetic & Clinical Features
Sydney 2005:
Translocation (4:14), Fibroblast Growth Factor Receptor 3 (FGFR3) and MM
Sydney 2005:
The Pharmacogenomics of Myeloma
Sydney 2005: Associations of Genetic Variation with Clinical Outcome: Update on Bank On A Cure
Sydney 2005: Microarray Exp. Profiling Indicates Upreg. of Ribosomal Machinery in del(13)-Neg Clone
Sydney 2005: Intensive v Double Intensive Tx in Untreated MM: Update of HOVON 24 MM
Sydney 2005: Single v Double HDT in MM: Second Analysis of the Trial GMMG-HD2
Sydney 2005: HDT / Stem Cell Support in MM: Update of the Spanish Studies (PETHEMA/GEM)
Sydney 2005: Double v Single ASCT & Role of Added Thal as First-line Tx for MM (Bologna 96 and 02)
Sydney 2005:
Update on High Dose Therapy: MAG Studies
Sydney 2005:
Update on High Dose Therapy: MRC Studies
Sydney 2005:
New Therapeutic Approaches in Myeloma Bone Disease
Sydney 2005: MIP-1a: Osteolytic & Tumour-Promoting Effects in MM Bone Disease
Sydney 2005:
RANK and MIP-1alpha in MM: Clinical Implications
Sydney 2005: Toward the Elucidation of the Role of Altered Wnt Signaling MM
Sydney 2005:
MIP-1 May Cause Reciprocal of Osteoclast and Dendritic Cell Diff. from Monocytes
Sydney 2005:
State of the Art of Allogenic Transplantation in MM
Sydney 2005:
What is the Role of Reduced Intensity Allogeneic Stem Cell Transplantation?
Sydney 2005:
High Dose or Reduced Intensity Conditioning for MM?
Sydney 2005: Strategies to Improve the Graft v MM Effect of Allo SCT & Donor Lymphocyte Infusions
Sydney 2005:
Efficacy of a 2nd Transplant with a 1st ASCTResults from a Spanish PETHEMA/GEM Study
Sydney 2005:
Bone Marrow Homing of MM Cell
Sydney 2005:
Role of the IGF-1/IGF-1 Receptor Pathway in the 5TMM Experimental Mouse Model
Sydney 2005:
AKT in MM: Therapeutic Implications
Sydney 2005: In MM Cells, Birn Pro-Apoptotic Functionis Neutralized Thru Endogenous Mcl-1/Birn ...
Sydney 2005: Inhibition of MM Cell Proliferation & Increase of Apoptosis thru Reg. of NF-kB & JNK...
Sydney 2005: Human Apurinic/Apyrimidinic Endonucleases (Ape1 & Ape 2) Leads to Genetic Instability
Sydney 2005: Bone Marrow Microvessel Endothelial Cells in MM Harbor MM-Assoc. Chromosomal Transloc.
Sydney 2005:
Coexpression of CD11a and CD45bright is the Hallmark of Proliferating Cell Malig.
Sydney 2005:
Bcl-xl, Myc, and Mutant Ras Transgenic Mouse Models of Plasma Cell Malignancies
Sydney 2005:
Final Results of IFM9904 Protocol: Dbl. Transplant +/- anti-IL6 Mono. Antibody in..
Sydney 2005: 1st Interim Analysis of Joint HOVON-GMMG-HD3 Randomised Study
Sydney 2005: Interim Analysis of the IFM 99-06 Trial on 350 Patients
Sydney 2005:
Tumor Immune Interactions in Myeloma
Sydney 2005:
T Cells in Myeloma: Lessons from a Murine Model
Sydney 2005:
Dendritic Cell Biology in Multiple Myeloma
Sydney 2005: Phenotypic and Functional Alterations of Gamma/Delta T Cells in Myeloma
Sydney 2005: The Role of Dendritic Cell Genotype in the Induction of T-Cell Responses...
Sydney 2005: A Phase I, Multi-Dose, Dose Escalation Study of SGN-40 (anti-huCD40 mAb) ...
Sydney 2005: Antagonist Anti-CD40 antibody CHIR-12.12 Causes Tumour Regr. & Prolongs Survival in MM
Sydney 2005: CHIR-258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Tx of t(4;14) MM
Sydney 2005: Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in MM Cells ...
Sydney 2005: In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase inhibitor, CYC202..
Sydney 2005: Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor
Sydney 2005: Combination of Tipifarnib & Bortezomib Results in Synergistic MM Cell death...
Sydney 2005: Cancer Vaccine Treatment and Antibody Therapy in MM
Sydney 2005: Tumour Lysate Dendritic Cell Vaccination in Multiple Myeloma
Sydney 2005: Tumor Antigen Immunization of Human Allotransplant Donors in Myeloma
Sydney 2005: DNA Vaccination Against Myeloma Post Autologous or Allogeneic Transplantation
Sydney 2005: Dendritic Cell-Based Vaccination and Beyond
Sydney 2005:
Drug Resistance in Multiple Myeloma
Sydney 2005: Anti-apoptotic Signalling in Multiple Myeloma Cells: Therapeutic Implications
Sydney 2005: Mechanisms of Drug Resistance Towards Thal and IMiDs in MM cells: role of C/EBPb
Sydney 2005: Lack of Mcl-1 Confers Resistance to Bortezomib and Melphalan but not Doxorubicin
Summary of the Xth International Myeloma Workshop
Myeloma Minute Special Edition: Updates from the International Myeloma Workshop in Sydney, Australia
IMF Presents Research Triple Play at Xth International Myeloma Workshop
Professor Jean-Luc Harousseau Receives Prestigious Waldenstrom Award
A Brief History of the International Myeloma Workshop
Update on Lenalidomide (CC-5013; Revlimid?)
Meet New Members of the IMF Scientific Advisory Board
Supportive Care: Erectile Dysfunction - Current Treatment Options
ASH 2004 - Rajkumar
ASH 2004 - Jagannath
ASH 2004 - Richardson
ASH 2004 - San Miguel
ASH 2004 - Dimopoulos
Report from the Atlanta 2005 Patient & Family Seminar
IMF Myeloma Bracelet - Imagine Moving Forward
Myeloma Minute - May 6, 2005
Bank On A Cure? Frequently Asked Medical Questions
Bank On A Cure? Scientific Advisory Board
Bank On A Cure? IMF Patient Programs and Services
Bank On A Cure? Brian Van Ness, Ph.D.
Bank On A Cure? Brian G.M. Durie, M.D.
Bank On A Cure? Susie Novis, President, International Myeloma Foundation
Bank On A Cure? Susie Novis, President, International Myeloma Foundation
IMF Hotline Coordinators Answer Your Questions
Supportive Care: Blood Tests
Dallas Patient & Family Seminar
Community Goals Lead to Results
IMF Receives Highest Four-Star Rating
Sorority Raises Funds for a Cure
Myeloma Foundation of Australia Inc.
Webcast of the Official Launch of BANK?ON?A?CURE?
So, What?s Up With Revlimid?
Myeloma Minute - May 16, 2005
2005 Brian D. Novis Research Grants
Did You Know: What Causes Hyperviscosity in Multiple Myeloma?
JC?s Support for Myeloma Patients Grows
Myeloma Minute - May 22, 2005
Myeloma Minute - July 10, 2005
I Have Myeloma....What's Next?
Team Milers Against Myeloma
San Diego Rock ?n Roll Marathon
First meeting of the Israeli Myeloma Working Group to be held on July 29, 2005
INTERNATIONAL NON-PROFIT DECORATES PACIFIC NORTHWESTERN MEDICAL COMMUNITY WITH ANNUAL RIBBON OF HOPE
Myeloma Minute - August 14, 2006
Myeloma Minute - July 3, 2005
Documentary Film Company Searching for Myeloma Patients Who Are Taking Thalidomide
Understanding Quadramet®
Myeloma Minute - July 31, 2005
Myeloma Minute - July 22, 2005
History is Made with the First Meeting of the Israeli Myeloma Study Group
Ministry Recap and Reflection - July 2005
Myeloma Minute - August 22, 2005
Multiple Colors for Multiple Myeloma
Myeloma Minute - September 2, 2005
Myeloma Minute - September 13, 2005
An old hometown needs help
ACTION ALERT! Congress Can?t Agree on Spending Bill.
International Myeloma Foundation Patient Handbook - Hebrew Edition
FDA postpones approval of Revlimid? for MDS
But Celgene says filing for myeloma remains on track
Patient Perspective: A Conversation with Tim and Donna Egan
Patient Perspective: Cancer Etiquette
Apprendimento VELCADE^® (bortezomib) per iniezione
Myeloma Minute - November 21, 2005
Third Annual Myeloma Days in Istanbul Draws Over 100 Attendees
Phase II VELCADE® Clinical Trials
Myeloma Minute - January 10, 2006
Myeloma Minute - October 28, 2005
Phase IV REVLIMID? Trial (Expanded Access Protocol or EAP)
REVLIMID? EXTENDS SURVIVAL WITH POSITIVE IMPLICATIONS FOR A WIDE RANGE OF BLOOD CANCERS
IMF Chair, Dr. Brian Durie, featured in Scientific American article DNA on the Loose: Next-Gen Blood Tests Tap Free-Floating Genetic Material
IMF Says Revlimid Approval Could Benefit Patients Throughout Europe
IMF: La recomendaci?n de la aprobaci?n de REVLIMID® puede beneficiar a pacientes en toda Europa
Der Vorschlag zur Genehmigung von REVLIMID(R) k?nnte sich laut der International Myeloma Foundation zum Patientenwohl in ganz Europa auswirken
Международный фонд борьбы с миеломой заявляет о том, что рекомендация одобрить REVLIMID(R) может помочь больным во всей Европе
La International Myeloma Foundation indique que la recommandation d'autorisation de mise sur le march? du REVLIMID(R) pourrait profiter aux patients de toute l'Europe
CAUTION ABOUT USE OF ERYTHROPOIETIN PRODUCTS
Kenneth C. Anderson Honored by IMF with 2005 Robert A. Kyle Lifetime Achievement Award
Over 200 Attend 2nd Annual Patient & Family Seminar in Madrid
Millennium invites Support Group Leader to XIth Myeloma Workshop in Kos, Greece
Over 300 In Attendance at Third Italian Patient & Family Seminar
ECOG REVLIMID? TRIAL HAS RESUMED
Myeloma Minute - November 7, 2005
Heinz Ludwig ASH 2005
Webcast of Dr. Hartmut Goldschmidt at ASH 2005
Webcast of Dr. Meryl Beksac at ASH 2005
Revlimid Update: Where Do We Stand?
Total Therapy III Update
Medicare Deadline Reminder
Un informe del Segundo Congreso Europeo para Enfermedades Hematol?gicas
Report from the 2nd European Congress on Hematological Malignancies
Living Successfully with Multiple Myeloma
Czech Patient & Family Seminar - September 2-3, 2005
Music Against Myeloma
Report from Madrid
I met Dr. Brian Durie more than 30 years ago...
Myeloma Minute - Special Edition:
FDA Grants 'Priority Review' for Revlimid
Don?t be misled by news reports that say thalidomide stops working for myeloma patients.
Myeloma Minute - March 14, 2006
Myeloma Minute - March 21, 2006
Fourth Annual Robert A. Kyle Lifetime Achievement Award Tribute Journal
Fourth Annual Robert A. Kyle Lifetime Achievement Award Event Details
Fourth Annual Robert A. Kyle Lifetime Achievement Award Sponsors
Verwirrende neue Geschichten ?ber die Effektivit?t von Thalidomid; was bedeutet dies?
Study Finds Patients Agree on Ideal Physician Behaviors
Eine Studie der Mayo-Klinik findet Patienten-Zustimmungzum idealen Verhalten von ?rzten
Mozobil ? ein neues Medikament zur Sammlung von Stammzellen
Kongressbericht: Symposium ?Das Multiple Myelom 2006: auf dem Weg zur Heilung??
Revlimid? Accepted by EMEA for Evaluation as Oral Therapy for Relapsed or Refractory MM
Myeloma Minute - April 5, 2006
Marktzulassungsantrag für LENOLIDAMID von EMEA zur Überprüfung angenommen
L'EMEA accepte d'?valuer la demande d'autorisation de mise sure le march? de la LENALIDOMIDE
La EMEA analiza la solicitud de comercialización de LENALIDOMIDA
Revlimid? Accepted by EMEA for Evaluation as Oral Therapy for Relapsed or Refractory MM
Myeloma Minute - April 11, 2006
Myelom Merkur - Ausgabe, April 2006
Our Guiding Light Shines Bright
16th Anniversary Gala Sponsors
Scheduled Speakers for the Fourth Annual Robert A, Kyle Lifetime Achievement Award
The IMF Launches Website for Global Spanish-Speaking Community
La IMF lanza un sitio Web para la comunidad mundial de habla espa?ola
Myeloma Minute - April 19, 2006
συνέντευξη - Dr. Meletios-Athanassios Dimopoulos
Polskie Stowarzyszenie Pomocy Chorym na Szpiczaka
The Yin and Yang of Long-Term Survivorship
American Society of Hematology - 47th Annual Meeting
Dear Reader
The Stafford Family Funds Myeloma Research Grant
Flavia Hiatt Shares Her Story
2006 IMF Brian D. Novis Research Grant Awards
Combination Therapy with VELCADE plus Melphalan & Prednisone
Pain Management in Multiple Myeloma
Transplant Nutrition
My Life With Myeloma
Challenging Cancer with the Power of Painting
Board of Directors Profile: Matthew Robinson
IMFers MAKE A DIFFERENCE!
2005 Member Fundraisers in Review
2005 Support Group Recap
Central Nebraska Myeloma Support Group
The IMF Returns to St. Petersburg, Russia
IMF Hotline Coordinators Answer Your Questions
Dalsu Baris, MD, PhD
House Budget Inaction Stalls Senate?s Cancer Funding Momentum
Myeloma Minute - April 26, 2006
Myeloma Minute - May 2, 2006
Mensajero del Mieloma
House Leadership Presses for Budget Bill Opposed by Health Advocates
Myeloma Minute - May 10, 2006
House Leadership Uses Obscure Procedural Move to Cap Spending Levels
Myeloma Minute - May 18, 2006
Dear Reader
Patient Perspectives: NUMBERS DON'T LIE, or do they?
IMF Around the Globe: Israeli Association of Myeloma Patients
Sixth Annual Support Group Leader Retreat
Making Clinical Trials More Patient-Friendly
Pathogenesis and Maintenance of Multiple Myeloma
MOZOBIL?, a potential new agent for Stem Cell Harvesting
Patient Experience: One Day at a Time...for 18 Years
Education, Advocacy, and Awareness: Profile of Robin Tuohy
IMF Hotline Coordinators Answer Your Questions
The Multiple Myeloma ListServe
IMF Around the Globe: ?The Greater Montreal Multiple Myeloma Support Group
Member Events: Gary C. Heuer, Jr. Memorial Golf Tournament
Fundraising: Rocking in Rhode Island
Fundraising: Katie's Birthday Charity Bash
South Florida's Dynamic Duo: Cindy Feltzin and Vicki Anderson Ferraro
IMF Board Member Interview with Benson and Carol Klein
Insights into New Myeloma Tx: Revlimid Study Tops List of Investigations that may Benefit Patients
Member Events: 4th Annual MMAMM Benefit Keeps Lee Grayson's Memory Alive
On the Road with the IMF Support Team
Advocacy Update: Senators Outraged by Decreased Research Funding
THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS FDA APPROVAL OF THALOMID? FOR MYELOMA PATIENTS
Myeloma Minute - May 24, 2006
Ralph Ferrizzi Memorial Golf Tournament
My Journey Through Myeloma
Myeloma Minute - May 31, 2006
ASCO 2006 Overview with Dr. Durie
Myeloma Minute - June 7, 2006
2006 IMF Support Group Leaders? Retreat
Report from ASCO 2006
ASCO 2006 INDUSTRY NEWS
Myeloma Minute - June 14, 2006
7th Annual JC Golf Tournament a Stellar Success!
IMF Receives Grant from Goldman Philanthropic Foundation for Bank On A Cure®
16th Anniversary Gala Sponsor Opportunities
2006 Robert A. Kyle Lifetime Achievement Award; Report from the Dinner Chairs
The International Myeloma Foundation Unveils Plans for MYELOMA MOBILE to Travel Across the U.S. this Summer
1845
AMEN's First Anniversary
AMEN's First Anniversary
Myeloma Minute - June 21, 2006
REVLIMID? APPROVAL FOR MYELOMA CAN BE LIFE-CHANGING FOR CANCER PATIENTS
Myeloma Minute Special Edition: Revlimid® Approved for Myeloma!
Prediction of response to therapy with clarithromycin/lenalidomide/dexamethasone (BIRD) in MM
Lenalidomide plus high-dose dex provides improved overall survival compared to high-dose dex alone
Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma.
Myeloma Minute - June 30, 2006
Correlation of bone marrow angiogenesis & response to thalidomide Dexamethasone in multiple myeloma
An Overview of Key Presentations at ASCO 2006
Un resumen de las presentaciones claves de ASCO 2006
Myeloma Minute - July 7, 2006
Partnership for Cure's Concert for Cures Nets $25,000 for Bank? On A Cure
An Overview of the Role of Novel Therapies in Previously Untreated Myeloma
Comparison of lenalidomide with dexamethasone to dex alone in patients who've received prior thalid
Multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dex vs dex
Dose-escalating & pharmacologic study of bortezomib in adult cancer pts with impaired renal function
Single-agent bortezomib in previously untreated MM:
Results of a phase II multicenter study.
Randomized, Active-controlled Study of Denosumab (AMG 162) in Breast Cancer Patients with
Rock On!
ASCO 2006: A Commentary
?Qu? es el Mieloma?
Update on Multicenter Atiprimod Trial
Myeloma Minute - July 26, 2006
Part I
AMEN Hosts Myeloma Seminar for Hematology Residents
Myeloma Minute - July 26, 2006
Part II
RUN THE NYC MARATHON AND FIGHT MYELOMA
ASCO 2006
ASCO 2006
ASCO 2006
Summer 2006 Myeloma Today in PDF
Spring 2006 Myeloma Today in PDF
Myeloma Minute - August 6, 2006
Leading Cancer Experts Conduct Philadelphia Seminar on MM Treatment as New 'Model' for Cancer Care
Comprendre Revlimid®
Comprendre La Dexaméthasone et Autres Stéroïdes
Out and About in Beverly Hills
Myelom Merkur - Ausgabe, August 2006
Myelom Merkur - Ausgabe, Mai 2006
An IMF tip-sheet: How to Round Out Your Trip to the IMF's 16th Anniversary Gala
Myeloma Minute - August 30, 2006
Myeloma Minute - May 1, 2007
Report from the 2nd Annual Czech Myeloma Group Patient Seminar
INTERIM FINDINGS FROM GLOBAL TRIAL EXTEND POSITIVE BENEFITS OF VELCADE TO NEWLY DIAGNOSED PATIENTS
Live Auction Items for the IMF's 16th Anniversary Gala on October 21
Igor Sill
THE INTERNATIONAL MYELOMA FOUNDATION SAYS THE KENNEDY-HUTCHISON CANCER BILL WILL REINVIGORATE WAR ON CANCER
E. Michael D. Scott
An American in Paris?
Myeloma Minute _ September 22, 2006
Have You Made Your New Year's Resolutions Yet!
ASH 2006 Highlights for Patients with Myeloma
Report from the 4th Annual Paris Patient & Family Seminar
Myeloma Minute - October 5, 2006
Report from the Fourth Annual Italian Patient & Family Seminar
Myeloma Minute - October 17, 2006
Understanding VELCADE® (bortezomib) for Injection Therapy
Understanding Thalidomide Therapy
Fall 2006 Myeloma Today in PDF
Conociendo Revlimid
What a Night! Report from the IMF's 16th Anniversary Gala
Myeloma Minute - November 3, 2006
New IMF Nurse Leadership Board Meets to Develop Recommendations for Care
The IMF in Atlanta
Myeloma Minute - November 11, 2006
Conociendo Dexametasona y Otros Esteroides
Das Handbuch zur Ballon Kyphoplastik „Ballon Kyphoplastik und Myelom-induzierte Wirbelfrakturen verstehen"
国際骨髄腫財団：国際癌会議における数々の研究報告。新治療方法に関して血液癌患者に明るい展望
 The Use of Velcade as First-Line Therapy in High-Risk Myeloma
The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
The Genetic Contribution to the Etiology of Thalidomide-Associated VTE
Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
A Phase I Study of Novel Proteasome Inhibitor PR-171 (carfilzomib)
Identification of Mutations in the NFkB Pathway That Predict Velcade Response
Velcade Added to High-Dose Cytoxan and GCSF as a Mobilization Regimen for Stem Cell Collection Prior to HDT

Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
A Randomized Study of Lenalidomide with High- or Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Myeloma
Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
SNP Association with Event-Free Survival (EFS) in Myeloma from Two Phase III Trials Using the Bank On A Cure SNP Chip

Relationship Between Quality of Response to Velcade and Clinical Benefit

A Phase I Study of HCD122 (formerly CHIR-12.12), a Monoclonal Antibody to CD40, in Relapsed/Refractory Myeloma

A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma

Analysis of Phase III Study of Revlimid/Dexamethasone vs. Dexamethasone Alone in Patients >65 Years

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma

An Analysis of Response Criteria Post-Stem Cell Transplant in AL Amyloidosis

An Overview of ASH 2006
Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma

Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma

New Proteasome Inhibitor NPI-0052

A Retrospective Analysis of Three Induction Regimens for Newly Diagnosed Myeloma Prior to Transplant

A Retrospective Analysis of the Significance of Measurable Disease at Time of Transplant

A Retrospective Analysis of High-Dose Therapy in Patients with Renal Insufficiency

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma

An Overview of ASH 2006
Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma in Patients with Elevated Baseline Serum Creatinine

Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma

An International Randomized Trial of Thalidomide/Dexamethsone vs Dexamethasone Alone

A Retrospective Study of the Significance of VGPR/CR in the IFM 99 Trials

An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma

Prospective Randomized Comparison of Double Transplant with Melphalan 200 vs Triple Transplant with Melphalan 100

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma

IMF Promotes David Smith to Executive Director
2007 Brian D. Novis Grant Winners Announced at ASH
Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma

Phase I Study of KOS-953 + Velcade in Patients with Relapsed/Refractory MM
A Retrospective Study of the Significance of Complete Response (CR) on Outcomes in Myeloma Treatment

A Subset of Revlimid/Dexamethasone vs Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
The Use of Velcade + Melphalan and Prednisone in Elderly Non-Transplant Patients

A Phase II Study of Alternating Velcade and Dexamethasone as Induction Therapy Prior to Transplant in Newly Diagnosed Patients

An Overview of Planned Randomized Clinical Trials for Newly Diagnosed Younger and Older Patients in Spain

Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma

Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma

Sue Sumpter's Blog from ASH 2006
Paula Van Riper's Blog from ASH 2006
Jack Aiello's Blog from ASH 2006
An Overview of ASH 2006
The IMF Mourns the Passing of Cathy Lebkuecher, winner of the Francesca Thompson Outstanding Service Award for her work with myeloma patients.
A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
ASH 2006 Güncel özet
The Effect of Genetically Modified Measles Virus on Myeloma Cells in Vitro

A Phase I/II Study of Consolidation Therapy with Velcade after Tandem Transplant

Winter 2006 Myeloma Today in PDF
German Translation of The Effect of Genetically Modified Measles....
German Translation for Consolidation Therapy video
STUDY SHOWS VELCADE® PLUS DOXIL® IMPROVES SURVIVAL IN PREVIOUSLY TREATED PATIENTS WITH MYELOMA
Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2006
The F.O.R. (Friends of Richie) Benefit Story
IMF's Multiple Myeloma Quilt of Courage 5
Overview of ASH 2006 in Hebrew

Multiple Myeloma Quilt of Courage #5 - To Honor Tom Finnerty
Myeloma Quilt of Courage #5 - In Memory of Rich Ramsaier
Multiple Myeloma Quilt of Courage #5 - To Military and Ex-Military
Multiple Myeloma Quilt of Courage #5 - To Honor Jerry Simpson
Multiple Myeloma Quilt of Courage #5 - By Reino Melse Meenks
Multiple Myeloma Quilt of Courage #5 - In Memory of Fritz Steppat
Multiple Myeloma Quilt of Courage #5 - In Memory of Jim Potter
Myeloma Quilt of Courage # 5 - By Karen Maru
Myeloma Quilt of Courage #5 - In Memory of Christal Mann Albert
Myeloma Quilt of Courage #5 - In Memory of Dick T. Jordan, Jr.
Myeloma Quilt of Courage #5 - In Memory of Tim Woomer
Myeloma Quilt of Courage #5 - In Memory of Nancy Ann Phillips
Myeloma Quilt of Courage #5 - For Walter (Peter) Carr
Myeloma Quilt of Courage #5 - For Stanley Sablock
Myeloma Quilt of Courage #5 - By Debbie Tidwell
Myeloma Quilt of Courage #5 - To Honor All Those on the ACOR Myeloma Listserv
Myeloma Quilt of Courage #5 - By Myde Stocker
Myeloma Quilt of Courage #5 - In Memory of Bill Bertsche
Myeloma Quilt of Courage #5 - In Memory of Claire E. Wehrlen
Turn Your Vacations Into Donations!
Support Group Leader Blogs from ASH 2006
Myeloma Minute - January 23, 2007
LEADING CANCER EXPERTS TO CONDUCT LOS ANGELES SEMINAR ON MYELOMA TREATMENT AS THE "NEW MODEL" FOR CANCER CARE
Myeloma Minute - February 3, 2007
INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS
Myeloma Minute - February 13, 2007
2005 Brian D. Novis Grant Winners
ASH 2006 Multiple Myeloma Highlights for Physicians
IMF Travel Advantage Newsletter
Your Travel Helps Fund the IMF
David H. Vesole, MD, PhD, FACP
Treatment of Newly Diagnosed Myeloma Based on Mayo Clinic's mSMART
Heather Cooper Ortner Named IMF Vice President of Development
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Myeloma Minute - April 5, 2007
THE INTERNATIONAL MYELOMA FOUNDATION SAYS ECOG RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
Scientific Advisory Board
CELGENE LAUNCHES NEW ?PATIENT SUPPORT COORDINATOR? PROGRAM AT IMF MEETING OF SUPPORT GROUP LEADERS IN PHOENIX
Route for Myeloma Mobile Finalized
New England Journal of Medicine Sites Myeloma as Concern for Firefighters at 9-11 Scene
IMF Satellite Symposium at ONS - a huge success!
Myelom Merkur - 3. Ausgabe, April 2007
Myelom Merkur - 5. Ausgabe, January 2007
Myelom Merkur - Januar 2007
2. Jahrgang, 1. Ausgabe
Myeloma Today Spring 2007 in PDF format
2nd Annual Music Against Myeloma Raises 10K for IMF
IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Myeloma Minute Special Edition: NEW DRUG COMBINATION - VELCADE® PLUS DOXIL® - APPROVED FOR MYELOMA
Myeloma Minute - May 22, 2007
URGENT Advocacy Alert for Myeloma Patients:Reimbursement at Risk for ESAs for Management of Anemia
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma.

Prediction of response and progression in multiple myeloma (MM) with serum-free light chains (sFLC): Corroboration of the International Myeloma Working Group (IMWG) criteria.

Current status of stem cell transplantation: When? How Many? Allogeneic v Autologous or Both?

A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma

Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.

Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma

Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.

Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma.

Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses.

COMUNICADO: La IMF dice que la aprobaci?n de REVLIMID(R) es un importante avance para los pacientes en Europa
La Fondation internationale du my?lome indique que l'autorisation de mise sur le march? de REVLIMID® par l'EMEA repr?sente un progr?s important pour les patients en Europe
Die internationale Myelom-Stiftung ist der Auffasung, dass die Marktzulassung von REVLIMID? durch die EMEA f?r die Patienten in Europa ein gro?er Fortschritt ist
2007 Robert A. Kyle Lifetime Achievement Award
KOS 2007: Solitary Bone and Extramedullary Plasmacytoma
KOS 2007: The role of Autologous Transplantation in Waldenstrom's Macroglobulinemia
KOS 2007: Establishment of an Amyloid-Forming Human Cell Line
KOS 2007: Serum Concentrations of Angiogenic Cytokines in Waldenstrom's Macroglobulinemia: The Ratio of Angiopoietin-1 to Angiopoietin-2 Correlate with Disease Severity
KOS 2007: Molecular Principles Underlying Myeloma
KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
KOS 2007: Molecular Lesions in Multiple Myeloma
KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
KOS 2007: The Scid-hu model for Multiple Myeloma
KOS 2007: Animal Models of Multiple Myeloma: An Overview
KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
KOS 2007: Pathophysiology of Myeloma Bone Disease
KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
DATA REPORTED AT A GLOBAL MEDICAL MEETING IN GREECE DEMONSTRATES IMPROVED SURVIVAL FOR A WIDE RANGE OF MYELOMA PATIENTS
KOS 2007: The Role of T-Cells in Multiple Myeloma
KOS 2007: Genetic Model of Multiple Myeloma
KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
KOS 2007: New Agents Targeting Myeloma Bone Disease
KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
THE NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION PRESENTS ?GUIDELINES FOR ENHANCED PATIENT CARE? AT INTERNATIONAL MEDICAL MEETING
KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
KOS 2007: Final Results of a Phase II PETHEMA Trial of Alternating Bortezomib and Dexamethasone as Induction Regimen Prior Autologous Stem Cell Transplantation (ASCT) in YOunger Patients with Multiple Myeloma (MM): Efficacy and Clinical Implications of Tumor Response Kinetics
KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
KOS 2007: Management of Toxicities from Novel Agents
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective?
Introduction
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Yes!
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? No!
KOS 2007: Targeting Beta 1 Integrin Mediated Survival Signals in Multiple Myeloma
KOS 2007: Response by SFLC and Marrow Flow Cytometry in MRC Myeloma IX
KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma
KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area
KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients
KOS 2007: Drug Resistance in Myeloma
Understanding ZIO-101
(Darinaparsin)
WALL OF MIRACLES CHAIRMAN'S CIRCLE
What is Myeloma?
Understanding Stem Cell Transplant
testing pommo system for minute...
KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents
KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Introduction

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Q & A

KOS 2007: The Importance of New and Evolving Response Criteria
KOS 2007: AKT as a Therapeutic Target in Multiple Myeloma
KOS 2007: DNA Vaccines to Suppress Myeloma
KOS 2007: Novel Immunotherapy Strategies in Multiple Myeloma
KOS 2007: Single VS Double Autologous Transplant
KOS 2007: Autologous Stem Cell Transplantation for MM: Analysis of Prognostic Factors
KOS 2007: The Role of Donor-Lymphocyte Infusion and Other Post-Transplant Strategies After Allografting in Multiple Myeloma
KOS 2007: Donor lymphocyte infusion and other posttransplant Strategies After Allografting in Multiple Myeloma
KOS 2007: European Myeloma Network: The Present and the Future
KOS 2007: Future Perspectives in the Management of Myeloma
KOS 2007: High-Resolution Mapping of Common Gains and Losses in Myeloma
KOS 2007: Microchips for Optimized Fish Screening in Myeloma
KOS 2007: Gene Expression Profiles as Prognostic Factors for High-Dose Therapy and Bortezomib in Patients with Multiple Myeloma
KOS 2007: Cathepsin G is Upregulated in Patients Treated with IMIDS
KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial
Kos 2007: Allogeneic Transplantation in Multiple Myeloma
KOS 2007: Is there still a place for high-dose therapy in the elderly myeloma patients?
KOS 2007: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
KOS 2007: AL Amyloidosis: Diagnosis and Prognosis
KOS 2007: AL Amyloidosis: Response, Assessment, and Treatment
KOS 2007: The Role of High-Dose Therapy in AL-Amyloidosis
KOS 2007: Light Chain Deposition Disease
KOS 2007: What?s New About the POEMS Syndrome?
KOS 2007: Paraproteinemia Related Neuropathies
Myeloma Today Summer 2007 in PDF format
MY MMAMM EXPERIENCE
Conociendo la t?cnica de detecci?n de Cadenas Ligeras Libres en suero
Watch a Short Video About the IMF
REPORT FROM AMEN'S SECOND ANNIVERSARY
Comprendere il Desametasone e gli Altri Steroidi
The International Myeloma Foundation Issues Prevention and Treatment Guidelines for Firefighters for High-Risk Cancer
Myeloma MInute - August 18,2007
Myeloma Minute - July 30, 2007
Myeloma Minute Special Edition - Concert for a Cause!
Understanding Anemia and Fatigue
We Mourn the Passing of IMF Board Member, Rich Saletan
Myelom Merkur - August 2007
ASCO 2007 Highlights for Patients
ASCO 2007 Highlights for Physicians
Comprendre les Tests des Cha?nes L?g?res Libres S?riques
Help Us Learn More About Myeloma Patients
Myeloma Minute Special Edition - Celebrating Peter Boyle
Myeloma Minute Subscription
JOURNAL EDITORIAL DOCUMENTS DRAMATIC INCREASE IN SURVIVAL SINCE THE 1980?S
Myeloma Minute - November 29, 2007
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Freie Leichtketten-Tests verstehen
L?čba thalidomidem
L?čba Velcade
L?čba Revlimidem
Myeloma Minute - November 21, 2007
THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW FINDINGS REPORTED AT GLOBAL CANCER CONFERENCE REQUIRE NEW WAYS TO EVALUATE TREATMENTS
Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Dr. Robert Kyle - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Durie - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Jes?s San Miguel - Novel Agents at the 49th Annual American Society of Hematology Meeting (ASH) 2007
Elijah Alexander: ASH 2007: A Patient's Perspective
Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy
Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
Dr. Boccadoro - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Dr. Beksac - ASH 2007 G?ncel ?zet
Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma

Dr. Gertz - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
Dr. Blad? - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of W?rzburg
Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
Dr. Blad? - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress
Dr. Einsele - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in W?rzburg
Dr. Liebisch - Ein ?berblick ?ber den Klinische Studien in Ulm
Dr. Rowe - Information From The 2007 Annual Meeting of the American Society of Hematology (ASH)
Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress
Dr. Beksac - ASH 2007 G?ncel ?zet
Dr. Hajek - ASH 2007 - celkov? přehled
Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma

Dr. Blade - Un resumen de las presentaciones de ASH 2007
What is Myeloma?
Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients

Dr. Harousseau - Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2007
2008 Brian D. Novis Grant Award Recipients Announced at ASH 2007
THE INTERNATIONAL MYELOMA FOUNDATION SAYS STUDY SHOWS 90% OVERALL RESPONSE FOR PATIENTS WITH NEW REVLIMID? COMBINATION
Dr. Avet-Loiseau - Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2007
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Dr. De la Rubia - Un resumen de las presentaciones de ASH 2007
Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
Myeloma Today Winter 2007 in PDF
Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
Dr. Sezer - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Berlin
Dr. Goldschmidt - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien der GMMG und in Heidelberg
Dr. Mergenthaler - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Stuttgart
Dr. Salwender - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Hamburg Altona
Planning for Treatment With or Without Transplant
Balancing Efficacy, Toxicity, and Quality of Life for the Patient with Multiple Myeloma
Rolf Pelzing - European Myeloma Platform (EMP)
Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling
Rolf Pelzing - European Myeloma Platform (EMP)
La Fondation Internationale du My?lome d?clare que le nouveau r?gime de traitement pour les patients plus ?g?s pourrait bient?t ?tre approuv? en Europe
The Founding of AMEN
A Patient's Story
IMF Patient Handbook
THE IMF SAYS NEWLY DIAGNOSED PATIENTS COULD BENEFIT FROM FDA "PRIORITY REVIEW" OF VELCADE® FOR FRONT-LINE USE
A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop

Bank On A Cure® Updates from ASH 2006
Progress Report: Bank On A Cure® Research Initiative
New! Understanding Doxil® in Myeloma
Pilot VELCADE® Clinical Trials
Una Notte Memorabile
Molecular Pathogenesis of MGUS and Multiple Myeloma
Myeloma Manager™
Personal Care Assistant™
International Myeloma Foundation Research Initiatives
IMF Public Service Announcement (PSA)
What Clinical Outcomes are You Looking to Achieve with Balloon Kyphoplasty on Your Cancer Patients?
Does the Bone Cement, Polymethylmethacrylate (PMMA), Do Anything to Tumor Cells
Do You Consider Balloon Kyphoplasty When Plasmacytoma is Present?
Does the Balloon Kyphoplasty Technique Increase the Introduction of Malignant Cells into the Spinal Canal or Bloodstream?
At What Stage of a Patient's Chemotherapy or Radiation Treatment Can They Receive a Balloon Kyphoplasty?
Physician Biographies
Can a Patient Receive a Balloon Kyphoplasty While Undergoing Chemotherapy?
What is Your Preferred Sequence with Balloon Kyphoplasty and Radiation Treatment?
Indications
How Quickly Have Patients Reported Pain Relief after Balloon Kyphoplasty?
Do You Have Any Concern that Inflating an Inflatable Balloon Tamp (IBT), Used During Balloon Kyphoplasty, May Push a Tumor Posteriorly?
Who is a Good Candidate for Balloon Kyphoplasty?
Adverse Effects
Disclosure Statement
Can Balloon Kyphoplasty be Performed in Severely Deformed Vertebral Bodies?
What's the Role of Balloon Kyphoplasty and Radiation for the Treatment of Cancer Related Vertebral Compression Fractures?
The Role of Vertebral Augmentation: Expert Opinions

Myeloma Today Spring 2008 in PDF
WHAT IS BANK ON A CURE®?
THE INTERNATIONAL MYELOMA FOUNDATION SAYS THALIDOMIDE APPROVAL IN EUROPE COULD PROVIDE SURVIVAL BENEFITS TO NEWLY DIAGNOSED MYELOMA PATIENTS
NURSE LEADERSHIP BOARD OF THE INTERNATIONAL MYELOMA FOUNDATION FINALIZES GUIDELINES TO HELP NURSES MANAGE AND PATIENTS COPE WITH THE SIDE EFFECTS OF THERAPY
Consensus on Care: New Insights on Novel Therapies in Multiple Myeloma
Myelom Merkur - Juli 2008
A TEA IN D.C.
THE INTERNATIONAL MYELOMA FOUNDATION SAYS NEW STUDIES SHOW LONGER SURVIVAL FOR MYELOMA PATIENTS AND IMPROVED RESPONSE TO TREATMENTS
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
5^ÈME SÉMINAIRE D'INFORMATION ET DE SOUTIEN AUX PATIENTS ET À LEUR FAMILLE
Paris 2007
Conversations at ASCO 2008:
Antonio Palumbo, MD
University of Torino and Italian Multiple Myeloma Study Group
Conversations at ASCO 2008:
S. Vincent Rajkumar, MD
Associate Professor of Medicine, Mayo Clinic
Myeloma Matrix VELCADE® Supplement
THE INTERNATIONAL MYELOMA FOUNDATION SAYS PREVIOUSLY UNTREATED PATIENTS COULD BENEFIT FROM FDA APROVAL OF VELCADE® FOR 'FRONT-LINE' USE
Report from the Third Anniversary of AMEN
Myeloma Minute - July 8, 2008
Myeloma Minute
May 18, 2008
Myeloma Minute
June 12, 2008
Myeloma Minute
May 8, 2008
Myeloma Minute
April 7, 2008
Myeloma Minute
March 28, 2008
Myeloma Minute
February 10, 2008
Myeloma Minute Special ASH Overview Issue
Press Alert & Happy Holidays from the IMF!!!
Conversations at EHA 2008
Heinz Ludwig, MD
Wilhelminen Hospital, Vienna, Austria

Conversations at EHA 2008
Roman H?jek, MD
Masaryk University, Brno, Czech Republic

Myeloma Today Summer 2008 in PDF
Myelom Merkur - Mai 2008
Myelom Merkur - M?rz 2008
Myelom Merkur - Dezember 2007
Myelom Merkur - Oktober 2007
Mensajero del Mieloma - Seminario en Valencia para pacientes y sus familias
How to Host an Afternoon Tea
Ask the Expert
Managing Side Effects of Novel Agents
Rx of Acute Compression Fractures with Balloon Kyphoplasty
How to Be a Better Patient
Myeloma 101
Standard Frontline Therapy
Understanding Serum Free Light Chain Assays
Stem Cell Transplantation in Multiple Myeloma
Bone Disease in Myeloma
How To Deal With Relapse?
Future Perspectives in Myeloma Management
Myeloma Minute
August 25, 2008
AN EDITORIAL BY DR. BRIAN DURIE FEATURED IN THE NEW ENGLAND JOURNAL OF MEDICINE
THE INTERNATIONAL MYELOMA FOUNDATION RECEIVES HEALTH IMPACT AWARD FOR EXCEPTIONAL SERVICE TO MYELOMA PATIENTS AND COMMUNITY
THE INTERNATIONAL MYELOMA FOUNDATION SAYS LIFE-CHANGING BENEFITS OF REVLIMID® RECOGNIZED BY THE PRESTIGIOUS PRIX GALIEN USA AWARD 2008
Dr. Brian G.M. Durie Research Publications Overview
THE INTERNATIONAL MYELOMA FOUNDATION SAYS PATIENT EXPERIENCE—LONGER SURVIVAL AND IMPROVED QUALITY OF LIFE—SUPPORTS ENCOURAGING DATA BEING PRESENTED AT THE ANNUAL HEMATOLOGY MEETING
Comprensione - Cifoplastica Percutanea con Palloncino e Fratture da Compressione Vertebrale indotte dal Mieloma
THE INTERNATIONAL MYELOMA FOUNDATION APPLAUDS EXPANSION OF VELCADE® FOR PREVIOUSLY UNTREATED PATIENTS IN EUROPE AND CANADA
Combined Federal Campaign (CFC)
Report from the Rome 2008 Patient and Family Seminar
The International Myeloma Foundation Praises UK REVLIMID? Proposal as Positive, Innovative Model for Reimbursement
The International Myeloma Foundation, the MDS Foundation and a Coalition of Patient Advocacy Organizations Call for Updated Rules for Reimbursement, Access and Approvals for New and Existing Cancer Treatments.
Dear Members of the IMF Community
THE INTERNATIONAL MYELOMA FOUNDATION ANNOUNCES NEW THREE-WAY RESEARCH AGREEMENT WITH NOBEL PRIZE WINNER LUC MONTAGNIER AND HOWARD URNOVITZ OF CHRONIX BIOMEDICAL
THE INTERNATIONAL MYELOMA FOUNDATION CALLS FOR ALL PATIENTS TO HAVE ACCESS TO THE NOVEL THERAPIES FOR MYELOMA
2nd Annual IMF Comedy Celebration Benefiting the Peter Boyle Memorial Fund Raises Over $600,000 for Myeloma Research
Dr. Rajkumar - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA

ASH 2008 - CASE STUDY 1: A MULTIPLE MYELOMA PATIENT INELIGIBLE FOR TRANSPLANTATION
"Evidence-Based Approaches for Transplant-Ineligible Patients"

ASH 2008 - CASE STUDY 2: A TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENT
"Role of Transplantation and Maintenance Therapy"

ASH 2008 - CASE STUDY 3: MULTIPLE MYELOMA PATIENT FOR WHOM TRANSPLANTATION ELIGIBILITY IS UNCERTAIN
"Evidence-Based Approaches for Induction Therapy"

Myeloma Today Fall 2008 in PDF
ASH 2008 - CASE STUDY 4: A MULTIPLE MYELOMA PATIENT WHO RELAPSES FOLLOWING INDUCTION THERAPY
"Novel Approaches for the Treatment of Relapsed/Refractory Myeloma"

Dr. Rajkumar - ASH 2008 - Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome
THE INTERNATIONAL MYELOMA FOUNDATION SAYS MOZOBIL? APPROVAL COULD BENEFIT MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTS
Dr. Ludwig - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
Dr. Ludwig - Ein ?berblick ?ber den ASH-Kongress 2008
Dr. Anderson - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA

Dr. Landau - ASH 2008 - Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response
Dr. San Miguel - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan?Prednisone Versus Melphalan?Prednisone in Newly Diagnosed Multiple Myeloma

Dr. San Miguel - ASH 2008 - Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Dr. San Miguel - Un resumen de las presentaciones de ASH 2008
Dr. Palumbo - ASH 2008 - A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients

Dr. Palumbo - ASH 2008 - Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients

Dr. Palumbo - ASH 2008 - Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results

Dr. Morgan - ASH 2008 - Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Dr. Morgan - ASH 2008 - High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma

Dr. Morgan - ASH 2008 - CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

Dr. Morgan - ASH 2008 - Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients

Dr. Beksac - ASH 2008 - HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM)

Dr. Beksac - ASH 2008 G?ncel ?zet
Dr. Zonder - ASH 2008 - Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

Dr. Lacy - ASH 2008 - Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Dr. Kumar - Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Dr. Kumar - ASH 2008 - Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Dr. Kumar - ASH 2008 - Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Dr. Lokhorst - ASH 2008 - Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Dr. Lokhorst - ASH 2008 - Overview of ASH 2008 in Dutch
Dr. Hajek - ASH 2008 - celkov? přehled
Dr. Hajek - ASH 2008 - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance

Dr. Salwender - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Hamburg Altona

Dr. Bensinger - ASH 2008 - A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Dr. Dispenzieri - ASH 2008 - Primary Therapy with Bortezomib?the Role of Induction, Maintenance, and Re-Induction in Patients with High Risk Myeloma. Update of Results from E2A02

Dr. Jakubowiak - ASH 2008 - Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Dr. Jakubowiak - ASH 2008 - Initial Treatment with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Dr. Lonial - ASH 2008 - A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Dr. Lonial - ASH 2008 - A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration

Dr. Knop - ASH 2008 - Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial
Dr. Knop - ASH 2008 - Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial

Dr. Petrucci - ASH 2008 - Efficacy and Safety of Re-Treatment with Bortezomib (Velcade?) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial

Dr. Reece - ASH 2008 - Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid?) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Dr. Reece - ASH 2008 - Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion

Dr. Reece - ASH 2008 - The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

Dr. Englehardt - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Freiburg
Dr. Kaufman - ASH 2008 - First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Dr. Pozzi - ASH 2008 - Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease

Dr. Santo - ASH 2008 - AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β
Dr. Barlogie - ASH 2008 - Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Dr. Gertz - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008 in San Francisco, CA and
Dr. Miki - ASH 2008 - KRN5500, a Spicamycin Derivative, Exerts Anti-Myeloma Effects through Impairing Both Myeloma Cells and Osteoclasts

Dr. Goldschmidt - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien der GMMG und in Heidelberg
Dr. Goldschmidt - ASH 2008 - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Dr. Goldschmidt - ASH 2008 - Inhibition of Aurora-Kinases for Tailored Risk-Adapted Treatment of Multiple Myeloma

Dr. Wijermans - ASH 2008 - Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

Dr. Van Ness - ASH 2008 - Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma

Dr. Vogl - ASH 2008 - Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Dr. Avigan - Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma
Dr. Gramatzki - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Keil
Dr. Blad? - ASH 2008 - Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade?)/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade? As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

Dr. Blad? - Un resumen de las presentaciones de ASH 2008
Dr. Vij - ASH 2008 - Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Dr. Drach - ASH 2008 - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Wein

Dr. Niederwieser - ASH 2008 - Overview of the European Bone Marrow Transplant Group (EBMT)

Dr. Weber - ASH 2008 - Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

Dr. Munshi - ASH 2008 - Alternate Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A High-Density Exon Array Analysis of Uniformly Treated Newly-Diagnosed Myeloma Patients

2009 Brian D. Novis Grant Award Recipients Announced at ASH 2008
Dr. Knop - Ein ?berblick ?ber den ASH-Kongress und Klinische Studien in Würzburg
Myelom Merkur - Dezember 2008
Myelom Merkur - September 2009
Overview of ASH 2008
Dr. Sonneveld - ASH 2008 - Overview of ASH 2008 in Dutch
Dr. Santo - ASH 2008 - Una visione d?insieme dell?ASH 2008
Dr. Bergsagel - ASH 2008 - The Genetic Origin of Myeloma
Dr. Cavo - ASH 2008 - Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma; Up-Front Response Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities
Dr. Cavo - ASH 2008 - Una visione d?insieme dell?ASH 2008
Dr. Wijermans - ASH 2008 - Overview of ASH 2008 in Dutch
Dr. Richardson - ASH 2008 -
Dr. Jagannath - ASH 2008 - Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma
Dr. Harousseau - ASH 2008 - Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan?Prednisone Versus Melphalan?Prednisone
Dr. Harousseau - ASH 2008 - Un R?sum? du Congr?s de la Societ? Am?ricaine d?Hematologie (ASH) 2008
Dr. Harousseau - ASH 2008 - Velcade-Dexamethasone versus VAD as Induction Treatment Prior to ASCT in Newly Diagnosed MM. Updated Results of the IFM2005/01 Trial.
Green Tea Blocks Benefits Of Cancer Drug
Genetic Changes in Myeloma: Prognostic Implications
IMF Live Webcast From the XIIth International Myeloma Workshop
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: Nurse Perspective
Redefining Risk Using Cytogenetics Changes
Role of FISH in Myeloma Risk Stratification
Role of FISH in Myeloma Risk Stratification
High Throughput Profiling in Myeloma Pathobiology and Prognosis
New Insights In to the Molecular Basis of MM Pathogenesis & Prognosis
Inhibition of Signaling Cascades by Histone Deacetylase Inhibitors & AKT
Role of Hsp90 in Myeloma
Using Kinase Directed SiRNA Screen to Study Signaling Cascade in Development of Drug Resistance
Targeting NFkB Signaling in Myeloma
Waldenströms Award Lecture
Novel Antigenic Targets for Immunotherapy in Myeloma
BAFF Signaling in Myeloma
Antibody-based Therapies in Multiple Myeloma
Targeting the Right Patients to Achieve Overall Survival and Time to Progression Benefits
Disease Control with active Long-Term Treatment
Cure Versus Control: Shifting the Treatment Paradigm in Newly Diagnosed Multiple Myeloma
Induction Therapy and Timing of ASCT
New Options for Elderly Patients with Newly Diagnosed Multiple Myeloma
Case Presentation and Interactive Case Discussion
Statement from the IMF on Insurance Inequities
Immunomodulation: The Cornerstone of the Treatment of Multiple Myeloma
Deep Vein Thrombosis (DVT) Prophylaxis
Management of problems with stem cell mobilization
Prevention & Management of Drug-Induced Peripheral Neuropathy in Myeloma
p62 - a Potential Target for Blocking Microenvironmental Support of Myeloma
Migration and Homing in Multiple Myeloma
Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature
The Effect of Novel Antimyeloma Agents on Bone Metabolism
(IFM) Phase III Studies that have been Completed by the IFM Group in Multiple Myeloma
(IFM) Phase III Studies That are On-going and Future Planned studies by the IFM Group in Multiple Myeloma
(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the US Groups in Multiple Myeloma
(US/Canada) "Phase III Studies That have been Completed, Ongoing and Planned by the Canadian Group in Multiple Myeloma
(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Italian and Spanish Groups in Multiple Myeloma
(Europe) "Phase III Studies That have been Completed, Ongoing and Planned by Various Northern European Groups in Multiple Myeloma
Lenalidomide, bortezomib, and dexamethasone has notable activity in high-risk frontline myeloma
Bortezomib, dexamethasone, cyclophosphamide, lenalidomide (VDCR) has high efficacy in frontline myeloma
Prolonged therapy improves quality of response, and CR associated with superior outcomes, with VMP
A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients
MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study
First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycin, Dexamethasone (PAD) vs VAD as induction treatment prior to High Dose Melphalan (HDM) in patients with multiple myeloma (MM)
Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma
Panobinostat & Bortezomib Phase I Trial in Multiple Myeloma
Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
Phase 2 Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
Extended follow-up results of BiRD therapy: prolonged responses achieved
MRC Myeloma IX: Preliminary Results From The Intensive Pathway Study
Lethal and bortezomib-sensitizing targets in myeloma identified by genome-scale RNAi Screening
DNA DSBs induction by Zalypsis, a novel marine compound, results in potent antimyeloma activity
Proteomic analysis of Multiple Myeloma identifies upregulation of the novel protein CRIK
aCGH in Vk*MYC mice identifies genetic changes shared with human MM
MicroRNA expression profiling in multiple myeloma: correlation with genetic abnormalities
Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis
Guidelines for the Uniform Reporting of Clinical Trials in Myeloma: Report of the IMW Consensus Panel
Guidelines for Stratification of Risk In Multiple Myeloma: Report of the IMW Consensus Panel
Guidelines for Standard Investigative Work-Up in Myeloma: Report of the IMW Consensus Panel
Statistical Issues in the Design and Analysis of Clinical Trials in Myeloma
New Mobilization and Conditioning Strategies
Timing of Transplant in the Era of New Drugs
Number - Single vs Double
Total Therapy
Allogeneic Transplant in Multiple Myeloma - Allografting for Myeloma: Mini? Maxi? Or Something in Between?
Post Transplant Maintenance
HOVON-50 Final Analysis of Thalidomide Combined with Adriamycine, Dexamethasone and HDM
Long-term Follow-up Results of IFM9903 and IFM9904 Rrials: RIC versus ASCT
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma ? a Prospective Trial
A Phase III Study of MEL200 versus MEL100 in Newly Diagnosed Myeloma Young Patients
Dex/Thal as Induction and Maintenance Treatment in Elderly Patients with MM : a Randomized Trial
A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
Post-ASCT Thalidomide Consolidation Further Prolongs PFS For Patients That Have Already Achieved A Complete or Very Good Partial Response
Len/Dex+/-Bortezomib for Advanced Myeloma According to Prior Neuropathy: the Impact of Cytogenetics
Management of Anemia in Multiple Myeloma Patients with Anemia: Findings from the A.C.T. Study
A Phase 3 Trial of Kyphoplasty Versus Nonsurgical Care for Cancer Patients with Vertebral Fractures
The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma ? An Update
Aurora-kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma
CAL-101 a Selective Inhibitor of PI3K p110δ for the Treatment of Multiple Myeloma
Targeting c-Myc Expressing Multiple Myeloma (MM) by Inhibiting Cyclin Dependent Kinase 1 (CDK1)
Efficacy and Safety of anti-b2M mAbs to Treat MM
IL21 Induces Myeloma Cell Growth via IGF1 Autocrine Loop
IL-17 Promotes Tumor Cell Growth & Survival, and Inhibits Immune Function in Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS): A Disease in Progression
Immunophenotyping of Plasma Cell Disorders
Can We Treat MGUS and Smouldering Myeloma?
Novel Agents in the Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Multiple Myeloma, and Skin Changes)
Understanding Pathogenesis to Improve Care in Amyloidosis
Improving Care for Patients with Amyloidosis
Pathogenesis, Biology and Diagnosis of Waldenstrom Macroglobulinaemia
Novel Treatment Options in Waldenstrom Macroglobulinaemia
Simultaneous use of Novel Agents in Induction Therapy
Sequential use of Novel agents in Induction Therapy
Therapy Should be Based on Risk Satisfaction - Favor
Therapy Should be Based on Risk Stratification - Against
Is there a role for Allo Tx? - Against
Is there a role for Allo Tx? - Favor
US/DFCI - New Agents
Early Combination Studies - "New Combination Approaches for MM"
New Proteasome Inhibitors
Anti Angiogenic Agents
Novel Bone Targeting Agents in Myeloma
New Imids
Lenalidomide Inhibits the Multiple Myeloma Cell-Survival Factor IRF4/MUM1
Centrosomal Clustering ? a Novel Therapeutic Target for Multiple Myeloma
Whole Body MRI in Asymptomatic Plasma Cell Disease
Is There a Place for Allogeneic Transplantation in Myeloma in the Era of Novel Agents?
Superiority of VTD Over TD Incorporated Into ASCT for Newly Diagnosed MM
Complete Response As A Marker Of Patient Outcomes
Improving Options For Frontline Management Of Multiple Myeloma
Evolving Treatment Options For Patients Not Eligible For Transplant
Optimizing Novel Therapies, Sequencing of Agents and Retreatment Options
Should Myeloma Therapy Be Based on Risk Stratification?
Future Directions in Multiple Myeloma Treatment. What can we Expect in the Next 10 Years?
Future Perspectives/Closing Ceremony
PRESENTATIONS FROM THE XIITH INTERNATIONAL MYELOMA WORKSHOP IN WASHINGTON, DC
FEBRUARY 26 - MARCH 1, 2009
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: Patient Perspective
The IMF is blogging from the XIIth International Myeloma Workshop in Washington, DC!
THE INTERNATIONAL MYELOMA FOUNDATION ? WEBCASTING LIVE FROM THE SCIENTIFIC SESSIONS AT THE XIIth INTERNATIONAL MYELOMA WORKSHOP
DR. BRIAN DURIE RECEIVES THE PRESTIGIOUS WALDENSTR?M?S AWARD IN RECOGNITION OF HIS MANY CONTRIBUTIONS TO THE FIELD OF MULTIPLE MYELOMA
March is IMF Myeloma Awareness Month!
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: What's of Importance to Patients for Their Future
Understanding Bisphosphonates Video with Japanese Subtitles
Myeloma Awareness Month 2009
International Myeloma Workshop 2009 Update: What's of Importance to Patients Today
International Myeloma Working Group Guidelines for Serum Free Light Chain Analysis in Multiple Myeloma and Related Disorders
Dr. Durie featured in BioWorld® Today article With Advances in Genomics, Exosomes Broaden Horizons
THE INTERNATIONAL MYELOMA FOUNDATION SAYS MEDICARE DECISION TO COVER PET SCANS CAN IMPROVE DISEASE STAGING AND TREATMENT PLANNING
Myeloma Today Spring 2009 in PDF
ASCO 2009: Jagannath: Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).
Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
Carfilzomib in Patients with Relapsed Multiple Myeloma (PX-171-004)
ASCO 2009 - Durie: Highlights
ASCO 2009 - Rajkumar: Highlights
ASCO 2009: Siegel: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2009: Vij, PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.
ASCO 2009: Shah: Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients.
ASCO 2009: Palumbo: A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients.
ASCO 2009: Baz: Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM).
ASCO 2009 - Brown: Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3).
ASCO 2009- Hofmeister: Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM).
ASCO 2009 - Anderson: Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.
ASCO 2009 - Anderson: Highlights
ASCO 2009 - Richardson: Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.
ASCO 2009 - Stadtmauer: Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients.
ASCO 2009 - Knop: Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial.
ASCO 2009 - Voorhees: A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2009 - Crowley: Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival.
ASCO 2009 - Kapoor: Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM).
ASCO 2009 - Niesvizky: PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results.
ASCO 2009 - Shaughnessy: Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3).
ASCO 2009 - Barlogie: Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials.
Do You Have an Opinion about Health Care?
ABC is soliciting questions or comments from viewers about health reform.

Messager de My?lome
Juin 2009
La International Myeloma Foundation e l'Associazione Schirinzi A. Mario uniscono le loro forze per la lotta contro il mieloma multiplo
Spotlight on MUSIC AGAINST MYELOMA
IMF ADVOCACY CENTERED ON PATIENT PRIORITIES
IMF Office of Government Affairs
Afternoon Tea in Washington DC
2009 Virtual Founders Summit
The IMF and Advocacy
Bringing the voices of the myeloma community to the current debate on health care reform and related issues
Advocacy Update - September 1, 2009
Statement on the passing of Senator Kennedy
To make a difference, you need to make your voice count!
THE INTERNATIONAL MYELOMA FOUNDATION POSTPONES WASHINGTON MEETING ON HEALTH REFORM
Comprendre la greffe de cellules souches
Film Star Goes Public About Multiple Myeloma
ПРОФИЛАКТИКА ТРОМБОЗА, СВЯЗАННОГО С ПРИМЕНЕНИЕМ ТАЛИДОМИДА И ЛЕНАЛИДОМИДА, ПРИ МИЕЛОМЕ
ЕДИНЫЕ МЕЖДУНАРОДНЫЕ КРИТЕРИИ ОБЪЕКТИВНОГО ЭФФЕКТА ПРИ МНОЖЕСТВЕННОЙ МИЕЛОМЕ
КОНСЕНСУС МЕЖДУНАРОДНОЙ РАБОЧЕЙ ГРУППЫ ПО МИЕЛОМЕ И РЕКОМЕНДАЦИИ ПО СОВРЕМЕННОЙ РОЛИ МЕТОДИК ВИЗУАЛИЗАЦИИ В ДИАГНОСТИКЕ И МОНИТОРИНГЕ МНОЖЕСТВЕННОЙ МИЕЛОМЫ
THE INTERNATIONAL MYELOMA FOUNDATION TO HOLD WASHINGTON MEETING ON DRUG REGULATION AND REIMBURSEMENT TO MAKE HEALTH REFORM MEANINGFUL AND COST-EFFECTIVE FOR PATIENTS WITH RARE CANCERS
Myeloma Today Summer 2009 in PDF
Current Options for Frontline Therapy
Dr. Brian Durie
New for 2009! IMF Holiday Cards
Michael McKean won in the first round of the Jeopardy! "Million Dollar Celebrity Invitational."
Understanding Scientific Literature
Allan Weinstein, PhD
The Small Print
Dr. Brian Durie
Ask-the-Experts
Open Forum Discussion with Dr. Brian G.M. Durie, Dr. Frederick Smith and Dr. Robert Kyle
How to Be a Good Patient
Michael Katz
Managing the Side effects of Novel Agents
Kena Miller,RN, MSN, FNP
Download the classic folksong Shenandoah to your iPod or Zune, and make a donation to the the IMF.
Role of Bone Marrow Transplant in the Treatment of Myeloma
Dr. Edward A. Stadtmauer

Multiple Myeloma: Relapsed Disease
Dr. Sagar Lonial

Mensajero del Mieloma - Oto?o 2009
Mensajero de Mieloma - Primavera 2009
Le Messager de My?lome - Automne 2009
Il Messaggero di Mieloma - Autunno 2009
Myelom Merkur - Juni 2009
Myelom Merkur - April 2009
Bone Disease in Multiple Myeloma
Dr. Brian Durie
IMF Advocacy
Greg Brozeit with Christine Murphy and Arin Assero

Myeloma 101/Overview
Dr. Robert Kyle

Understanding Serum Free Light Chain Assays
Dr. Karen Van Hoeven